Fuller & Thaler Asset Management, Inc. Biogen Inc. Transaction History

Fuller & Thaler Asset Management, Inc.

$23.1 Billion
Q2 2024

A detailed history of Fuller & Thaler Asset Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Fuller & Thaler Asset Management, Inc. holds 3,930 shares of BIIB stock, worth $793,074. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,930

Previous 2,190 79.45%

Holding current value

$793,074

Previous $472,000 93.01%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$190.52 - $236.72 $331,504 - $411,892	1,740 Added 79.45%	3,930 $911,000
Q1 2024 May 13, 2024	SELL	$212.02 - $267.71 $1,696 - $2,141	-8 Reduced 0.36%	2,190 $472,000
Q4 2023 Feb 13, 2024	BUY	$222.59 - $267.94 $138,450 - $166,658	622 Added 39.47%	2,198 $568,000
Q3 2023 Nov 13, 2023	BUY	$253.3 - $285.89 $25,330 - $28,589	100 Added 6.78%	1,576 $405,000
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $107,347 - $124,043	390 Added 35.91%	1,476 $420,000
Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $148,434 - $180,351	-588 Reduced 35.13%	1,086 $301,000
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $107,079 - $147,653	-550 Reduced 24.73%	1,674 $447,000
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $243,802 - $289,926	-1,300 Reduced 36.89%	2,224 $454,000
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $19,958 - $25,146	103 Added 3.01%	3,524 $742,000
Q4 2021 Feb 09, 2022	SELL	$223.92 - $287.77 $111,960 - $143,885	-500 Reduced 12.75%	3,421 $821,000
Q3 2021 Nov 10, 2021	SELL	$282.99 - $369.05 $84,897 - $110,715	-300 Reduced 7.11%	3,921 $1.11 Million
Q2 2021 Aug 13, 2021	SELL	$259.0 - $414.71 $181,300 - $290,297	-700 Reduced 14.22%	4,221 $1.46 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $218,655 - $256,167	-900 Reduced 15.46%	4,921 $1.38 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $2,598 - $3,911	11 Added 0.19%	5,821 $1.43 Million
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $517 - $685	2 Added 0.03%	5,810 $1.55 Million
Q1 2020 May 06, 2020	SELL	$268.85 - $341.04 $1.71 Million - $2.16 Million	-6,346 Reduced 52.21%	5,808 $1.84 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $463,226 - $640,067	2,105 Added 20.95%	12,154 $3.61 Million
Q2 2019 Aug 13, 2019	BUY	$219.29 - $241.72 $398,888 - $439,688	1,819 Added 22.1%	10,049 $2.35 Million
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $409,365 - $640,295	-1,889 Reduced 18.67%	8,230 $1.95 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $754,735 - $955,952	-2,710 Reduced 21.12%	10,119 $3.05 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $910,468 - $1.19 Million	-3,102 Reduced 19.47%	12,829 $4.53 Million
Q1 2018 May 14, 2018	SELL	$260.13 - $367.91 $155,297 - $219,642	-597 Reduced 3.61%	15,931 $4.36 Million
Q4 2017 Feb 12, 2018	SELL	$307.64 - $344.58 $945,070 - $1.06 Million	-3,072 Reduced 15.67%	16,528 $5.27 Million
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $98,402 - $115,391	350 Added 1.82%	19,600 $6.14 Million
Q2 2017 Aug 14, 2017	BUY	N/A	19,250	19,250 $5.22 Million

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $29.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.

Account

Fuller & Thaler Asset Management, Inc. Biogen Inc. Transaction History